RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform
RBC Capital reiterated its Sector Perform rating on PTC Therapeutics (PTCT) with an $85 price target, citing its strong balance sheet and early-stage pipeline. The company's Q2 2026 earnings of $0.92 per share on $361M revenue beat estimates. PTCT completed a gene therapy acquisition and raised its full-year outlook. Cantor Fitzgerald raised its price target to $137, maintaining an Overweight rating.
How this was made
The 30-second read
Why it matters
The reiteration does not change the stock's outlook given the earnings and acquisition are already known.
Market read
The piece is a recap of previously released earnings and acquisition details, offering little new trading insight.
What to watch
Potential future pipeline developments beyond the reported acquisition are not covered.
Background
RBC Capital reiterates a Sector Perform rating and $85 price target for PTCT, citing balance‑sheet strength and acquisition interest.
Ticker impact
The article recaps PTC Therapeutics' Q2 2026 earnings and its recent acquisition of ST-920, repeating figures already released on July 30.
neutral outlook as the news is a recap of previously disclosed information
All financial metrics and the acquisition were disclosed earlier; the article provides no fresh data to shift expectations.
Market effects
Biotech sector sees no immediate impact from this recap.
U.S. market unaffected.
Limited to investors tracking PTC Therapeutics.
Counterpoint
If investors missed the earnings beat, a short‑term bounce could occur.
Key entities
- CompanyPTC Therapeutics
Biotech firm focused on rare diseases.
- AnalystRBC Capital
Equity research firm providing rating and price target.
